People with glaucoma are typically scheduled for follow-up appointments every three to six months. During each visit, the doctor measures intraocular pressure (IOP) within a few minutes, checks the reading, and decides whether to maintain or adjust the medication. For the rest of the time, however, little is known about how IOP fluctuates or whether it spikes while the patient is sleeping. A sensor-equipped contact lens was developed to address this gap, and newer generations are even being designed to automatically release medication when pressure increases.

Smart contact lenses integrating sensors and microelectronic systems are being studied to monitor changes in intraocular pressure.
Current Challenges in Intraocular Pressure Management
Glaucoma is a leading cause of irreversible blindness worldwide, affecting approximately 3.5% of people aged 40 to 80. Elevated intraocular pressure is the main risk factor, and lowering IOP is the only intervention proven to slow disease progression. However, managing IOP presents two major challenges.
- Intraocular pressure is not constant. IOP fluctuates throughout the day, often reaching its peak at night or in the early morning when patients are not at the clinic. In people with glaucoma, pressure spikes may occur between appointments without causing noticeable symptoms, silently damaging the optic nerve. Yet eye drop dosages are often adjusted based on occasional pressure measurements taken at the clinic, sometimes several months apart.
- Eye drops are easily lost and frequently forgotten. According to one expert assessment, approximately 95% of the active ingredients in eye drops are washed away through the tear drainage system. Combined with the painless nature of glaucoma, inconsistent medication use is very common. This is why researchers are developing devices capable of both continuous monitoring and timely drug delivery.
What Are Smart Contact Lenses?
Smart contact lenses are soft contact lenses equipped with extremely small sensors, sometimes combined with electronic circuits, antennas, or drug reservoirs. Rather than correcting myopia or hyperopia, these lenses transform a conventional contact lens into a medical device positioned directly against the eyeball.
The measurement principle is relatively easy to understand. The cornea is an elastic tissue. When intraocular pressure rises, the cornea expands slightly, causing extremely small changes in its curvature. Because the contact lens closely follows the corneal surface, its sensors can detect these changes and use them to estimate whether the pressure is increasing or decreasing.
This technology currently follows two distinct approaches, each at a very different stage of development.
First Approach: Contact Lenses for Intraocular Pressure Monitoring
A representative example is Triggerfish, developed by Sensimed, a Swiss company. This soft silicone contact lens has received approval from the U.S. Food and Drug Administration (FDA) for extended monitoring of intraocular pressure. The lens contains microsensors that continuously measure changes in corneal curvature, allowing relative fluctuations in IOP to be assessed. The device is worn for 24 hours, providing a much more comprehensive picture than a single pressure measurement taken during a clinic visit.
There are three important points to understand about this device:
- It shows fluctuations in intraocular pressure throughout the day and night but does not provide absolute pressure measurements in mmHg like standard tonometers used in clinics.
- It must be prescribed and interpreted by medical professionals and is not currently a consumer product that patients can purchase and use independently.
- Clinical studies have reported common adverse effects, including temporary blurred vision, conjunctival redness, and superficial punctate keratitis.
Experts also emphasize that further research is needed to determine how data collected by these lenses should be interpreted, particularly which patterns of IOP fluctuation indicate a higher risk of disease progression.
Second Approach: Contact Lenses Combining Diagnosis and Treatment
Scientists refer to these devices as “theranostic” contact lenses, a term combining therapy and diagnostics. The concept involves a closed-loop system: a sensor detects rising intraocular pressure, a drug reservoir releases the appropriate dose at the right time, IOP decreases, and the sensor detects the change and stops drug delivery.

A smart contact lens model combining intraocular pressure sensors with a drug delivery system
Two notable approaches are currently being investigated:
Contact lenses with integrated electronic circuits. In 2022, a South Korean research team introduced a prototype featuring gold nanowire-based IOP sensors, a flexible drug reservoir, wireless circuitry, and a low-power control chip. The system can release timolol on demand to control intraocular pressure and has successfully monitored and regulated IOP in rabbits with experimentally induced glaucoma. Timolol is a commonly used active ingredient in glaucoma eye drops.
Battery-free, all-polymer contact lenses. A study published in Science Translational Medicine in 2026 attracted attention because its design completely eliminated electronic components. When intraocular pressure changes, the cornea changes shape, altering the shape of the contact lens and the volume of an embedded microfluidic chamber. This triggers drug release without requiring a battery or electronic circuits. The lens is designed to be replaced weekly, and its wearing period could potentially be extended by increasing its drug storage capacity. The electronics-free design makes the lens softer, lighter, and more comfortable than prototypes containing rigid electronic components.
Both prototypes have so far been tested only in rabbits, with one also evaluated using isolated bovine eyes. The researchers have stated that their next step is to collaborate with clinical partners on a small human trial to assess practical feasibility. This means that glaucoma patients cannot currently purchase or be prescribed a contact lens that automatically releases medication.
Potential Benefits of Smart Contact Lenses
If smart contact lenses successfully complete human clinical trials, they could bring three significant improvements:
- Continuous data instead of occasional measurements. Doctors could monitor IOP fluctuations throughout the day and night, detecting pressure spikes that would otherwise go unnoticed.
- More personalized treatment adjustments. Instead of making medication decisions based on a single pressure reading, doctors could evaluate each patient’s individual IOP fluctuation patterns.
- One ophthalmology expert has suggested that combining real-time monitoring with drug delivery could help address the problem of inconsistent medication use among patients.
Remaining Challenges
There is still a long way to go before this technology moves from the laboratory to routine clinical practice. The first challenge is safety: contact lenses can reduce oxygen availability to the cornea and create conditions that encourage microbial growth. Therefore, lenses containing additional sensors and medication, especially those designed for prolonged wear, must be proven not to increase the risk of infection. The second challenge is maintaining the stability of both the medication and sensors in the moist, protein-rich environment of the tear film. The third challenge is dosage: the amount of medication that can be stored in a thin contact lens is very limited, while glaucoma requires long-term management over many years. Finally, other barriers include cost, data privacy standards for health information transmitted to smartphones, and the development of interpretation thresholds that help doctors determine when the collected data is reliable enough to guide treatment adjustments.
What Should Glaucoma Patients Do Right Now?
While this technology is still being developed, the most practical steps involve maintaining good treatment habits:
- Use prescribed eye drops consistently and at the correct times, even when there are no noticeable symptoms. This remains the most common standard treatment approach.
- Attend regular follow-up appointments for intraocular pressure measurements, visual field testing, and optical coherence tomography (OCT) scans according to the doctor’s schedule.

Regular eye examinations help doctors monitor eye health and recommend appropriate tests to evaluate glaucoma.
- Ask your ophthalmologist about ways to monitor intraocular pressure outside regular clinic visits, such as handheld home tonometers for suitable patients or measurements taken at different times of the day.
- Do not use cosmetic contact lenses, self-purchased lenses, or devices from unreliable sources with the expectation that they can “monitor eye health.” Conventional contact lenses do not have the ability to measure or treat intraocular pressure.
- Inform your doctor immediately if you experience severe eye pain, rapidly worsening blurred vision, halos around lights, or headaches accompanied by red eyes.
Smart contact lenses could introduce an entirely different approach to glaucoma management. Instead of waiting several months to determine whether the disease is progressing, patients and doctors may eventually be able to monitor changes on an hourly basis. Nevertheless, until human clinical trials provide sufficient evidence, using prescribed eye drops correctly and attending regular eye examinations remain the most reliable ways to protect vision.
The information provided in this article is for general educational purposes only and does not replace professional eye examinations, medical advice, or treatment recommendations from an ophthalmologist.







